• Henan Genuine was established in September 2012.

• Submitted an IND clinical trial application for azvudine for treatment of HIV infection and received approval from the NMPA for the commencement of a Phase I clinical trial for azvudine for treatment of HIV infection in the PRC in April 2013.

• Commenced the Phase I clinical trial for azvudine for treating HIV in the PRC in July 2014.

• Completed the Phase I clinical trial for azvudine for treating HIV in the PRC in June 2015 .

• Received approval from the NMPA to conduct a Phase II clinical trial forazvudine for treating HIV in the PRC in December 2015.

• Commenced the Phase II clinical trial for azvudine for treating HIV in the PRC in October 2017.

• Completed the Phase II clinical trial for azvudine for treating HIV in the PRC in January 2019.

• Received approval from the NMPA to conduct a Phase I/Phase II clinical trial for dosimertinib for treating advanced EGFR mutation-positive non-small cell lung cancer (NSCLC) in the PRC in April 2020.

• Submitted an IND application to the NMPA to directly initiate a Phase Ⅲ clinical trial for azvudine for treating COVID-19 in the PRC, received approval in April 2020 and commenced the Phase Ⅲ clinical trial in 2020 June .

• We authorized Beijing Union to submit an IND application to the Ministry of Health of the Russian Federation for initiating a Phase Ⅲ clinical trial of azvudine for treating COVID-19 in Russia in 2020, and received an IND approval in January 2021 and commenced the Phase Ⅲ clinical trial in June 2021.

• Completed the Series A Investment in February 2021 and raised approximately RMB149.5 million.

• Authorized Beijing Union and an Independent Third Party agent to submit an IND application to the Brazilian Health Regulatory Agency for initiating a Phase Ⅲ clinical trial of azvudine for treating COVID-19 in Brazil and received approval in March 2021 and commenced the Phase Ⅲ clinical trial in June 2021.

• Obtained a conditional approval of azvudine from the NMPA for treating HIV in the PRC in July 2021.

• Completed the Phase Ⅲ clinical trial for azvudine for treating COVID-19 in the PRC in March 2022 .

• Completed the Series B Investment in April 2022 and raised approximately RMB563.3 million.

• Obtained a conditional approval from the NMPA of azvudine for treating common COVID-19 in adults in the PRC in July 2022.

• Entered into a strategic cooperation agreement with Fosun Pharmaceutical Industrial in July 2022 and launched the commercial sales of azvudine for the treatment of COVID-19 in the PRC in August 2022.

• Azvudine became the only domestic oral drug for the treatment of COVID-19 that has been listed in the Diagnosis and Treatment Plan for COVID-19 Infection （《新型冠状病毒感染诊疗方案》） in August 2022.

• Initiated the Phase Ⅲ clinical trial of azvudine for the treatment of HIV infection in August 2022.

• Received an IND approval from the NMPA for CL-197 for the treatment of HIV infection in October 2022.

• Azvudine, was included in the NRDL in April 2023.

• Commenced the Phase I clinical trial of CL-197 for the treatment of HIV infection in the PRC in August 2023.

• As of January 2024, the terminal sales of azvudine exceeded 10 million bottles and azvudine became one of the top-selling drugs for treating COVID-19 worldwide.

• Completed an investigator-initiated open-label clinical trial of azvudine to evaluate its efficacy and safety for the treatment of various late-stage solid tumors,including, among others, NSCLC, liver cancer and colorectal cancer, in March 2024.

• Obtained the IND approval from the NMPA for the clinical trials of azvudine in patients with advanced solid tumors in September 2024.

• Regained the complete commercialization right over azvudine for the treatment of COVID-19 and HIV infection in the PRC through an amendment agreement entered into with Fosun Pharmaceutical Industrial in September 2024.

• Completed the NRDL renewal regarding azvudine, with the scope and price of payment remaining unchanged, in November 2024.

• Submitted IND application for the combination therapy of azvudine anddosimertinib for the treatment of NSCLC in November 2024.

• In December 2024, the 240 mg dose group of the clinical trial of single-drug dosimertinib therapy showed significant efficacy and non-target lesions disappeared in the tested subjects.

• Obtained the ethical committee approval over the Phase IIa clinical trial of CL-197 for the treatment of HIV in September 2025. CDE reviewed the Phase IIa trial design in October 2025 and expressed no objection.

• Obtained the IND approval of azvudine + dosimertinib for the treatment of NSCLC in September 2025 and initiated a Phase I/IIa trial in November 2025.

• Submitted the IND application for the Phase II clinical trial of azvudine monotherapy for the treatment of blood cancers, received acceptance notification in September 2025 and obtained the IND approval in December 2025.

• Completed the last visit of the last patient under the Phase Ⅲ clinical trial of azvudine for the treatment of HIV in June 2025.

• Completed the Phase I clinical trial of dosimertinib for the treatment of NSCLC in May 2025 , and initiated the Phase II clinical trial in June 2025.

• Completed the Phase I clinical trial of CL-197 for the treatment of HIV in March 2025.

• Initiated Phase I clinical trial of azvudine in patients with advanced solid tumors in the PRC in January 2025 and completed such trial in June 2025.

• In January 2025, submitted a communication application to the CDE for the conversion of the conditional approval for the COVID-19 indication to regular approval. We submitted the conversion application in July 2025.

• Submitted an application for a conversion from conditional approval for the HIV indication of azvudine to a regular approval in April 2026.

• Obtained the IND approval of azvudine + anti-PD-1 for the treatment of liver cancer and colorectal cancer in February 2026.